By Michael Dabaie

Adaptive Biotechnologies Corp. said it has begun enrolling a virtual clinical study as part of a broader effort with Microsoft Corp. to rapidly map and measure the immune response to the Covid-19 virus.

Adaptive said the work seeks to inform improved diagnostics to fulfill the need for more reliable testing.

The study calls for 1,000 participants in U.S. metropolitan areas impacted by Covid-19. De-identified data will be made freely available to public health officials, academia and industry to help accelerate solutions to the pandemic, Adaptive said.

LabCorp, through its Covance drug development business, will manage the collection of blood samples and nose/throat swabs from participants in their own homes.

Adaptive Biotechnologies shares were up 2% to $33.06 in midday trading.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

May 05, 2020 12:41 ET (16:41 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Microsoft (NASDAQ:MSFT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Microsoft Charts.
Microsoft (NASDAQ:MSFT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Microsoft Charts.